A novel glycopeptide-based PKM2 nano-activator has been developed to selectively accumulate in tumor-enriched regions, suppressing aerobic glycolysis in BC cells by sequestering PKM2 tetramers and preventing dimeric nuclear translocation. This evidence concerns the gene PKM and neoplasm.